<DOC>
	<DOCNO>NCT00142116</DOCNO>
	<brief_summary>The purpose study determine percentage people attain remission length time responses therapy sustain , well side effect might result rituximab thalidomide people lymphoplasmacytic lymphoma .</brief_summary>
	<brief_title>Thalidomide Rituximab Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>- Patients receive thalidomide ( 200mg ) orally daily two week . If two week thalidomide , patient well dose thalidomide increase ( 400mg ) remain 50 additional week . The length time patient thalidomide depend upon respond therapy . - During second week study patient also begin receive rituximab intravenously weekly 4 week , may repeat 8 week later depend upon response . - A determination patient respond make base test conducted 12 week . This test include blood test possibly bone marrow biopsy . If determined disease progressing , patient begin second phase treatment include 4 additional weekly infusion rituximab continuation oral thalidomide . - If determine 12-week evaluation , time thereafter , disease progress ( study serum immunoglobulin M ( IgM ) level , bone marrow involvement , tumor cell , and/or development new sign symptom ) patient remove study . - Periodic examination test do determine patient , response side effect ( ) patient may study drug . If patient respond therapy remain study follow period two year . - Bone marrow biopsy aspiration obtain 3-6 month interval extend 2 year follow last treatment .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Clinicopathological diagnosis Waldenstrom 's macroglobulinemia require therapy Baseline staging requirement Absolute Neutrophil Count &gt; 500/microliter ( uL ) Platelet Count &gt; 25,000/uL Serum creatinine &lt; 2.5mg/dL Total bilirubin transaminase ( SGOT ) &lt; 2.5 X Upper Limit Normal ( ULN ) Greater 18 year age Life expectancy 3 month great Eastern Cooperative Oncology Group ( ECOG ) status performance 02 Chemotherapy , steroid therapy , radiation therapy within 30 day study entry Pregnant lactate woman Serious comorbid disease Uncontrolled bacterial , fungal viral infection Active second malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>thalidomide</keyword>
	<keyword>rituximab</keyword>
	<keyword>Waldenstrom 's</keyword>
</DOC>